Pliant Therapeutics Inc (NASDAQ: PLRX) started the day on Wednesday, with a price increase of 12.37% at $12.63, before settling in for the price of $11.24 at the close. Taking a more long-term approach, PLRX posted a 52-week range of $10.22-$18.92.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was -41.09%. Meanwhile, its Annual Earning per share during the time was -22.68%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -32.31%. This publicly-traded company’s shares outstanding now amounts to $60.85 million, simultaneously with a float of $53.76 million. The organization now has a market capitalization sitting at $768.58 million. At the time of writing, stock’s 50-day Moving Average stood at $13.64, while the 200-day Moving Average is $13.00.
Pliant Therapeutics Inc (PLRX) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Pliant Therapeutics Inc’s current insider ownership accounts for 11.66%, in contrast to 96.23% institutional ownership. According to the most recent insider trade that took place on Jul 10 ’24, this organization’s Chief Medical Officer sold 12,319 shares at the rate of 11.56, making the entire transaction reach 142,408 in total value, affecting insider ownership by 213,052. Preceding that transaction, on Jul 10 ’24, Company’s Chief Business Officer sold 9,900 for 11.56, making the whole transaction’s value amount to 114,444. This particular insider is now the holder of 227,494 in total.
Pliant Therapeutics Inc (PLRX) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.98 per share during the current fiscal year.
Pliant Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -32.31% and is forecasted to reach -3.99 in the upcoming year.
Pliant Therapeutics Inc (NASDAQ: PLRX) Trading Performance Indicators
Let’s observe the current performance indicators for Pliant Therapeutics Inc (PLRX). It’s Quick Ratio in the last reported quarter now stands at 10.26. The Stock has managed to achieve an average true range (ATR) of 0.86.
In the same vein, PLRX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.34, a figure that is expected to reach -0.99 in the next quarter, and analysts are predicting that it will be -3.99 at the market close of one year from today.
Technical Analysis of Pliant Therapeutics Inc (PLRX)
If we take a close look at the recent performances of Pliant Therapeutics Inc (NASDAQ: PLRX), its last 5-days Average volume was 0.38 million that shows plunge from its year to date volume of 0.38 million. During the previous 9 days, stock’s Stochastic %D was recorded 30.25% While, its Average True Range was 0.88.
Raw Stochastic average of Pliant Therapeutics Inc (PLRX) in the period of the previous 100 days is set at 40.99%, which indicates a major fall in contrast to 49.77% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 72.38% that was higher than 61.60% volatility it exhibited in the past 100-days period.
